FDA approves Ceptaris' Valchlor gel for cutaneous T-cell lymphoma

08/26/2013 | Pharmaceutical Business Review Online

The FDA has granted Ceptaris Therapeutics approval to market its Valchlor gel for treatment of patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma who previously received skin-directed treatment. The approval makes Valchlor gel the only FDA-cleared formulation of mechlorethamine, or nitrogen mustard.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Principal OptoMechanical Engineer - 14000008M2
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
San Jose, CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA